摘要
目的:观察固本消瘤胶囊加减方及其联合吉非替尼对非小细胞肺癌PC9及吉非替尼耐药株PC9GR细胞的增殖、迁移、凋亡及细胞周期的影响。方法:应用MTT法检测细胞增殖能力;细胞划痕实验检测细胞的迁移能力;流式细胞术观察细胞的凋亡和周期。结果:固本消瘤胶囊加减方与吉非替尼可呈浓度依赖性抑制PC9及PC9GR细胞的增殖,且联合用药后具有显著的增效作用(P<0.05);两药均可减弱两种细胞的划痕修复能力,联合用药同样具有显著的增效作用(P<0.05);两药均可显著增加细胞的凋亡率,且联合用药组细胞凋亡率显著高于两个单药组(P<0.05),同时各组用药对两种细胞的G0/G1期均产生了不同程度的抑制,但联合用药的抑制作用弱于单用吉非替尼(P<0.05)。结论:固本消瘤胶囊加减方可以显著抑制PC9及PC9GR细胞的增殖、迁移,其作用机制与诱导细胞凋亡、阻滞细胞周期有关;同时该方与吉非替尼联合应用在抑制细胞增殖、迁移,诱导细胞凋亡方面具有明显的增效作用。
Objective:To observe the effects of modified Guben Xiaoliu Capsules(GBXL)and GBXL combined with Gefitinib on the proliferation,migration,apoptosis and cycle of non-small cell lung cancer PC9 and Gefitinib-resistant PC9GR cells.Methods:MTT method was used to detect the proliferation of cells.Cell scratch test was used to detect the effect of drugs on cell migration.The apoptoticrate and division cycle of the two types of cells were detected by flow cytometry.Results:GBXL and Gefitinib inhibited the proliferation of PC9 and PC9GR cells in a concentration-dependent manner,and the combination group has a significant synergistic effect(P<0.05).GBXL and Gefitinib both weakened the scratch repair ability of the two types of cells compared with the blank group,and the combination group has a significant synergistic effect(P<0.05).GBXL and Gefitinib can significantly increase the apoptosis rate of the cells,and the apoptosis rate in the combination group was significantly higher than that in the single drug group(P<0.05),and the drug in each group inhibited the G0/G1 phase of the two cell division cycles to different degrees,but the blocking effect of the combined drug on the two-cell cycle is weaker than that of Gefitinib alone(P<0.05).Conclusion:GBXL can significantly inhibit the proliferation and migration of PC9 and PC9GR cells,the mechanism of which is related to the induction of apoptosis and the blockage of the cell cycle,and the combined medicine has obvious synergistic effect in inhibiting cell proliferation and inducing apoptosis.
作者
李光达
马云飞
张甘霖
于明薇
马婷婷
陈欣洁
李冰雪
程培育
王笑民
LI Guang-da;MA Yun-fei;ZHANG Gan-lin;YU Ming-wei;MA Ting-ting;CHEN Xin-jie;LI Bing-xue;CHENG Pei-yu;WANG Xiao-min(Graduate School,Beijing University of Chinese Medicine,Beijing 100029,China;Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2021年第6期3568-3571,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
北京中医医院院级课题暨两院合作课题(No.YJ-201803)
国家自然科学基金项目(No.81873111,No.81673924)
北京市自然科学基金项目(No.7202066)
国家“十三五”重大新药创制专项(No.2019ZX09734001)。
关键词
固本消瘤胶囊加减方
吉非替尼
非小细胞肺癌细胞
耐药
生物学行为
联合用药
增效
Modified Guben Xiaoliu Capsules
Gefitinib
Non-small cell lung cancer
Drug resistance
Biological behavior
Combined medicine
Synergistic effect
